Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE

BACKGROUND. Metastatic breast cancer (MBC) is highly prevalent in middle‐aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group for Geriatric Oncology) was designed to assess t...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Leo, Silvana, Arnoldi, Ermenegildo, Repetto, Lazzaro, Coccorullo, Zaira, Cinieri, Saverio, Fedele, Palma, Cazzaniga, Marina, Lorusso, Vito, Latorre, Agnese, Campanella, Giovanna, Ciccarese, Mariangela, Accettura, Caterina, Pisconti, Salvatore, Rinaldi, Antonio, Brunetti, Cosimo, Raffaele, Mimma, Coltelli, Luigi, Spazzapan, Salvatore, Fratino, Lucia, Petrucelli, Luciana, Biganzoli, Laura
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2018
Предметы:
Breast Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656485/
https://ncbi.nlm.nih.gov/pubmed/30413667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0676
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы